Celyad Oncology Sa Stock Performance
| CLYYF Stock | USD 0.15 0.03 16.67% |
The firm shows a Beta (market volatility) of 1.53, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Celyad Oncology will likely underperform. At this point, Celyad Oncology SA has a negative expected return of -1.2%. Please make sure to confirm Celyad Oncology's standard deviation, skewness, as well as the relationship between the Skewness and day typical price , to decide if Celyad Oncology SA performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Celyad Oncology SA has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain nearly stable which may send shares a bit higher in January 2026. The current disturbance may also be a sign of long-run up-swing for the company stockholders. ...more
| Begin Period Cash Flow | 17.2 M | |
| Total Cashflows From Investing Activities | -126 K |
Celyad |
Celyad Oncology Relative Risk vs. Return Landscape
If you would invest 41.00 in Celyad Oncology SA on September 30, 2025 and sell it today you would lose (26.00) from holding Celyad Oncology SA or give up 63.41% of portfolio value over 90 days. Celyad Oncology SA is currently producing negative expected returns and takes up 6.7406% volatility of returns over 90 trading days. Put another way, 60% of traded pink sheets are less volatile than Celyad, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Celyad Oncology Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Celyad Oncology's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Celyad Oncology SA, and traders can use it to determine the average amount a Celyad Oncology's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1778
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CLYYF |
Based on monthly moving average Celyad Oncology is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Celyad Oncology by adding Celyad Oncology to a well-diversified portfolio.
Celyad Oncology Fundamentals Growth
Celyad Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Celyad Oncology, and Celyad Oncology fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Celyad Pink Sheet performance.
| Return On Equity | -0.93 | |||
| Return On Asset | -0.29 | |||
| Current Valuation | 11.81 M | |||
| Shares Outstanding | 22.59 M | |||
| Price To Book | 5.05 X | |||
| Price To Sales | 24,222 X | |||
| EBITDA | (24.73 M) | |||
| Cash And Equivalents | 6.1 M | |||
| Cash Per Share | 0.39 X | |||
| Total Debt | 2.87 M | |||
| Debt To Equity | 0.15 % | |||
| Book Value Per Share | 1.36 X | |||
| Cash Flow From Operations | (26.64 M) | |||
| Earnings Per Share | (1.51) X | |||
| Total Asset | 79.94 M | |||
About Celyad Oncology Performance
By analyzing Celyad Oncology's fundamental ratios, stakeholders can gain valuable insights into Celyad Oncology's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Celyad Oncology has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Celyad Oncology has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor-T cell-based therapies for the treatment of cancer. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium. Celyad Oncology operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 87 people.Things to note about Celyad Oncology SA performance evaluation
Checking the ongoing alerts about Celyad Oncology for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Celyad Oncology SA help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Celyad Oncology SA generated a negative expected return over the last 90 days | |
| Celyad Oncology SA has high historical volatility and very poor performance | |
| Celyad Oncology SA has some characteristics of a very speculative penny stock | |
| Celyad Oncology SA has high likelihood to experience some financial distress in the next 2 years | |
| Celyad Oncology SA has accumulated 2.87 M in total debt with debt to equity ratio (D/E) of 0.15, which may suggest the company is not taking enough advantage from borrowing. Celyad Oncology SA has a current ratio of 0.95, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Celyad Oncology until it has trouble settling it off, either with new capital or with free cash flow. So, Celyad Oncology's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Celyad Oncology SA sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Celyad to invest in growth at high rates of return. When we think about Celyad Oncology's use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (26.51 M) with profit before overhead, payroll, taxes, and interest of 5 K. | |
| Celyad Oncology SA has accumulated about 6.1 M in cash with (26.64 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.39, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing Celyad Oncology's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Celyad Oncology's stock is overvalued or undervalued compared to its peers.
- Examining Celyad Oncology's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Celyad Oncology's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Celyad Oncology's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Celyad Oncology's pink sheet. These opinions can provide insight into Celyad Oncology's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Celyad Pink Sheet analysis
When running Celyad Oncology's price analysis, check to measure Celyad Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Celyad Oncology is operating at the current time. Most of Celyad Oncology's value examination focuses on studying past and present price action to predict the probability of Celyad Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Celyad Oncology's price. Additionally, you may evaluate how the addition of Celyad Oncology to your portfolios can decrease your overall portfolio volatility.
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |